This article provides a status report on the global burden of cancer worldwide using the
GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International …

Despite its good initial response and significant survival benefit in patients with castration-
resistant prostate cancer (CRPC), taxane therapy inevitably encounters drug resistance in …

Emerging data have linked certain features of clinical prostate cancer (PC a) to obesity and,
more specifically, increased adiposity. Whereas the large number of clinical studies and …

Rapid developments in imaging and treatment with radiopharmaceuticals targeting prostate
cancer pose issues for the development of guidelines for their appropriate use. To tackle this …

Background: Previous work determined that early life exposure to low-dose Bisphenol A
(BPA) increased rat prostate cancer risk with aging. Herein, we report on prostate-specific …

Background Multiple statistical models predicting lymph node involvement (LNI) in prostate
cancer (PCa) exist to support clinical decision-making regarding extended pelvic lymph …

Prostate cancer remains the second most prevalent cancer in men. Its incidence,
progression and mortality profiles vary significantly by race and ethnicity, with African …

Cancer is a major cause of illness in Australia and therefore ongoing monitoring of cancer in
Australia is important. This study sources data from the Australian Institute of Health and …

Prostate cancer is one of the most common cancers in men worldwide. Currently available
diagnostic and prognostic tools for this disease, such as prostate specific antigen, suffer from …

Abstract The phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathways and Bcl-2 family
play a central role in prostate cancer (PC). The aim was to determine influence in the …